Compare Vanguard Total International Bond Index Fund ETF (BNDX) vs Cardinal Health Inc (CAH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Vanguard Total International Bond Index Fund ETF vs Cardinal Health Inc — how do they compare? Vanguard Total International Bond Index Fund ETF trades at $47.87, while Cardinal Health Inc trades at $236.13 (market cap $55.88B). The key difference: Cardinal Health Inc pays a 0.86% dividend while Vanguard Total International Bond Index Fund ETF pays none, and Cardinal Health Inc is trading nearer its 52-week high, Vanguard Total International Bond Index Fund ETF nearer its low. Which is the better fit depends on your goals.
| BNDX | CAH | |
|---|---|---|
52-Week High | $49.91 | $240.26 |
52-Week Low | $47.57 | $146.04 |
Market Cap | — | $55.88B |
Sector | — | Health |
Enterprise Value | — | $59.91B |
Dividend Yield | — | 0.86% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BNDX trades at $47.91, up 0.25% with neutral technical signals. The ETF shows mixed institutional activity with Apella Capital reducing holdings by 3.0% while Archer Investment increased by 48.2% in Q2 2026. Recent dividend payments of $0.11-$0.12 provide income appeal, though key valuation ratios remain unavailable for analysis.
Outlook remains balanced amid bond market volatility. Rising Treasury yields and inflation concerns create headwinds, while institutional interest and steady dividends offer support. The ETF's international bond exposure provides diversification benefits but remains sensitive to global interest rate movements and geopolitical tensions.
Cardinal Health (CAH) trades at $237.18, up 0.33% on the day, near its 52-week high. The stock shows bullish technical signals with consistent earnings beats, including Q2 2026 EPS of $2.91 versus $2.42 expected. Revenue reached $222.58 billion in 2025, with net income margin improving to 0.67%. Positive sentiment is driven by strong Q4 2026 results and optimistic fiscal 2027 guidance highlighted by Reuters on August 11, 2026.
Outlook remains favorable with analyst consensus price target of $266.43 implying 12% upside. Key opportunities include pharmaceutical segment strength and dividend payments, while risks involve high debt levels and thin profit margins. The bullish analyst stance (54.55% buy ratings) supports growth potential, but investors should monitor cash flow volatility and competitive pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Vanguard Total International Bond Index Fund ETF
The fund employs an indexing investment approach designed to track the performance of the Bloomberg Global Aggregate ex-USD Float Adjusted RIC Capped Index (USD Hedged). This index provides a broad-based measure of the global, investment-grade, fixed-rate debt markets. It is non-diversified.
Read more on BNDX →About Cardinal Health Inc
Cardinal Health is a leading pharmaceutical wholesaler, engaged in the sourcing and distribution of branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail-order), hospitals networks, and healthcare providers. Along with AmerisourceBergen and McKesson, the three compose well over 90% of the U.S. pharmaceutical wholesale industry. Cardinal Health also supplies medical-surgical products and equipment to healthcare facilities in North America, Europe, and Asia.
Read more on CAH →
